Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.64 |
| ▸ | BACE1 | P56817 | 4/20 | 0.64 |
| ▸ | AKR1B10 | O60218 | 4/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | CA5A | P35218 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3921921 | 0.98 | GSK3B (0.61) | GSK3BBACE1AKR1B10AKR1B1LMNA | |
| SCHEMBL6539306 | 0.88 | GSK3B (0.68) | GSK3BBACE1AKR1B10AKR1B1LMNA | |
| SCHEMBL6539315 | 0.88 | GSK3B (0.68) | GSK3BBACE1AKR1B10AKR1B1LMNA | |
| SCHEMBL15687588 | 0.87 | LMNA (0.77) | GSK3BBACE1AKR1B10AKR1B1LMNA | |
| SCHEMBL15687587 | 0.87 | LMNA (0.77) | GSK3BBACE1AKR1B10AKR1B1LMNA | |
| SCHEMBL19088247 | 0.87 | APP (0.68) | LMNACA12CA7CA9CA14 | |
| SCHEMBL19244249 | 0.87 | APP (0.68) | LMNACA12CA7CA9CA14 | |
| SCHEMBL2187265 | 0.85 | EGFR (0.49) | GSK3BBACE1AKR1B10AKR1B1LMNA | |
| SCHEMBL3355331 | 0.85 | EGFR (0.49) | GSK3BBACE1AKR1B10AKR1B1LMNA | |
| Butyl Cinnamate SCHEMBL119511 | 0.85 | APP (0.65) | AKR1B10AKR1B1LMNAMAOBAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20060257987-A1 | Ppar modulators | ELI LILLY AND COMPANY | 2006-11-16 | — | — | US | disclosed |
| EP-1706386-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2006-09-14 | — | — | US | disclosed |
| EP-1660428-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1585726-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005066136-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2004063155-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | PPARA, PPARG, PPARD | GSK3B 4628/4885BACE1 3756/4885AKR1B10 1903/4885 |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | PPARD, PPARA, PPARG | GSK3B 4125/4885BACE1 3232/4885AKR1B10 484/4885 |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | PPARA, PPARG, PPARD | GSK3B 4699/4885BACE1 3507/4885AKR1B10 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.